DK2879691T3 - Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira - Google Patents
Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira Download PDFInfo
- Publication number
- DK2879691T3 DK2879691T3 DK13750235.7T DK13750235T DK2879691T3 DK 2879691 T3 DK2879691 T3 DK 2879691T3 DK 13750235 T DK13750235 T DK 13750235T DK 2879691 T3 DK2879691 T3 DK 2879691T3
- Authority
- DK
- Denmark
- Prior art keywords
- disabling
- creative
- wear
- compositions
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13061—Methods of inactivation or attenuation
- C12N2740/13063—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680039P | 2012-08-06 | 2012-08-06 | |
| PCT/US2013/053781 WO2014025771A2 (en) | 2012-08-06 | 2013-08-06 | Methods and compositions for inactivating enveloped viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2879691T3 true DK2879691T3 (da) | 2019-06-11 |
Family
ID=48986268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13750235.7T DK2879691T3 (da) | 2012-08-06 | 2013-08-06 | Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10188732B2 (enExample) |
| EP (2) | EP2879691B1 (enExample) |
| JP (2) | JP6465800B2 (enExample) |
| DK (1) | DK2879691T3 (enExample) |
| WO (1) | WO2014025771A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2879691B1 (en) | 2012-08-06 | 2019-03-27 | Biogen MA Inc. | Methods for inactivating enveloped viruses |
| CA2961510A1 (en) | 2014-09-17 | 2016-03-24 | Helixbind, Inc. | Methods and devices for detecting and identifying microorganisms |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| EP3420341B1 (en) * | 2016-02-24 | 2020-11-18 | Bio-Rad Laboratories, Inc. | Methods and compositions for fluorescence detection |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| BR112019006689A2 (pt) | 2016-10-25 | 2019-06-25 | Regeneron Pharma | métodos e sistemas para análise de dados de cromatografia |
| EP3446710A1 (en) * | 2017-08-25 | 2019-02-27 | Glenmark Pharmaceuticals S.A. | Methods of inactivating viral contaminants |
| KR102790861B1 (ko) | 2017-09-18 | 2025-04-08 | 바이엘 헬쓰케어 엘엘씨 | N-메틸글루카미드 및 그의 유도체를 사용한 바이러스 불활성화 방법 |
| US12042538B2 (en) | 2017-09-19 | 2024-07-23 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| SG11202003793WA (en) | 2017-10-30 | 2020-05-28 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| MX2021005685A (es) | 2018-11-15 | 2021-07-07 | Bayer Healthcare Llc | Metodos de inactivacion virica para la fabricacion continua de anticuerpos. |
| WO2020190985A1 (en) * | 2019-03-19 | 2020-09-24 | Amgen Inc. | Alternate detergents for viral inactivation |
| CN110424030B (zh) * | 2019-08-30 | 2020-06-30 | 广州三孚新材料科技股份有限公司 | 无氰碱性电镀铜液及其制备和在挠性印刷线路板中的应用 |
| US20230183656A1 (en) * | 2020-05-14 | 2023-06-15 | Merck Patent Gmbh | Methods and compositions for purifying adeno associated virus particles or adenoviruses |
| US11643641B2 (en) | 2021-03-04 | 2023-05-09 | Malireddy S. Reddy | Prevention of viral transmission by naked genetic material |
| CN117836010A (zh) | 2021-06-21 | 2024-04-05 | 优尼科生物制药有限公司 | 改进的裂解程序 |
| EP4626230A1 (en) | 2022-11-29 | 2025-10-08 | Merck Patent GmbH | Method for inactivating enveloped viruses |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE242716C (enExample) | ||||
| DD242716A3 (de) | 1981-08-28 | 1987-02-11 | Adw Der Ddr Inst F Chem Techno | Verfahren zur herstellung von gereinigten antigenen bzw. biopraeparaten |
| DE3704550A1 (de) * | 1987-02-13 | 1988-08-25 | Behringwerke Ag | Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5314917A (en) | 1991-03-22 | 1994-05-24 | E. B. Michaels Research Associates, Inc. | Method for inactivating enveloped viruses and sperm |
| FR2805163A1 (fr) | 2000-02-21 | 2001-08-24 | Pf Medicament | Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale |
| US6635679B2 (en) * | 2001-05-14 | 2003-10-21 | Akzo Nobel N.V. | Methods and compositions for inactivating viruses |
| JP2007517057A (ja) | 2003-12-30 | 2007-06-28 | ワイス | 改善された耐容性を有する免疫原性組成物中の疎水性タンパク質の処方物 |
| NZ568211A (en) * | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EP1970440A1 (en) | 2007-03-06 | 2008-09-17 | Qiagen GmbH | Polymerase stabilization by ionic detergents |
| BR112013015113B1 (pt) * | 2010-12-15 | 2023-01-31 | Takeda Pharmaceutical Company Limited | Método de inativar um vírus contendo envelope lipídico |
| GB201216121D0 (en) * | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| EP2879691B1 (en) | 2012-08-06 | 2019-03-27 | Biogen MA Inc. | Methods for inactivating enveloped viruses |
-
2013
- 2013-08-06 EP EP13750235.7A patent/EP2879691B1/en active Active
- 2013-08-06 JP JP2015526635A patent/JP6465800B2/ja active Active
- 2013-08-06 DK DK13750235.7T patent/DK2879691T3/da active
- 2013-08-06 WO PCT/US2013/053781 patent/WO2014025771A2/en not_active Ceased
- 2013-08-06 US US14/419,968 patent/US10188732B2/en active Active
- 2013-08-06 EP EP18200752.6A patent/EP3456352A1/en active Pending
-
2018
- 2018-10-09 JP JP2018190622A patent/JP6833788B2/ja active Active
- 2018-12-06 US US16/211,302 patent/US10702603B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2879691A2 (en) | 2015-06-10 |
| WO2014025771A2 (en) | 2014-02-13 |
| US10702603B2 (en) | 2020-07-07 |
| US10188732B2 (en) | 2019-01-29 |
| EP2879691B1 (en) | 2019-03-27 |
| JP2015525572A (ja) | 2015-09-07 |
| US20190175738A1 (en) | 2019-06-13 |
| JP6833788B2 (ja) | 2021-02-24 |
| US20150306223A1 (en) | 2015-10-29 |
| WO2014025771A3 (en) | 2014-04-17 |
| JP6465800B2 (ja) | 2019-02-06 |
| EP3456352A1 (en) | 2019-03-20 |
| JP2019037234A (ja) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2879691T3 (da) | Fremgangsmåder og sammensætninger til inaktivering af kappebærende vira | |
| DK2890780T3 (da) | Fremgangsmåder og sammensætninger til behandling af en genetisk tilstand | |
| DK3875104T3 (da) | Sammensætninger til behandling af ineffektiv erytropoiese | |
| DK2773635T3 (da) | Forbindelser og sammensætninger til modulering af EGFR-aktivitet | |
| DK3363901T3 (da) | Sammensætninger og fremgangsmåder til præcis identificering af mutationer | |
| DK2812452T3 (da) | Fremgangsmåder og sammensætninger til screening og behandling af udviklingsforstyrrelser | |
| DK2914741T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet | |
| DK2906696T3 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
| DK2838917T3 (da) | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler | |
| DK2911506T3 (da) | Driftreducerende sammensætninger | |
| LT2742151T (lt) | Polimerazės kompozicija | |
| BR112013022112A2 (pt) | composição | |
| DK3241547T3 (da) | Lyofiliseret præparat af botulinumtoksin | |
| DK2665486T3 (da) | Sammensætninger til modulering af gamma-c-cytokin-aktivitet | |
| BR112013022102A2 (pt) | composição | |
| DK2766483T3 (da) | Fremgangsmåder og sammensætninger til screening for og behandling af udviklingsforstyrrelser | |
| DK2855500T3 (da) | Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| BR112014004395A2 (pt) | composição | |
| BR112014032798A2 (pt) | composição | |
| DK2830654T3 (da) | Metoder og sammensætninger til behandling af inflammation | |
| DK2922955T3 (da) | Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression | |
| EP2842163A4 (en) | NONLINEAR MEMRISTORS | |
| BR112013033808A2 (pt) | composição | |
| EP2730619A4 (en) | COMPOSITION |